Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis
File(s)PIIS155252601630022X.pdf (1.61 MB)
Published version
Author(s)
Type
Journal Article
Abstract
Introduction: The aim of this study was to (1) replicate previous associations between six blood lipids
and Alzheimer’s disease (AD) (Proitsi et al 2015) and (2) identify novel associations between lipids, clinical
AD diagnosis, disease progression and brain atrophy (left/right hippocampus/entorhinal cortex).
Methods: We performed untargeted lipidomic analysis on 148 AD and 152 elderly control plasma
samples and used univariate and multivariate analysis methods.
Results: We replicated our previous lipids associations and reported novel associations between
lipids molecules and all phenotypes. A combination of 24 molecules classified AD patients with
.70% accuracy in a test and a validation data set, and we identified lipid signatures that predicted
disease progression (R2 5 0.10, test data set) and brain atrophy (R2 0.14, all test data sets except
left entorhinal cortex). We putatively identified a number of metabolic features including cholesteryl
esters/triglycerides and phosphatidylcholines.
Discussion: Blood lipids are promising AD biomarkers that may lead to new treatment strategies.
and Alzheimer’s disease (AD) (Proitsi et al 2015) and (2) identify novel associations between lipids, clinical
AD diagnosis, disease progression and brain atrophy (left/right hippocampus/entorhinal cortex).
Methods: We performed untargeted lipidomic analysis on 148 AD and 152 elderly control plasma
samples and used univariate and multivariate analysis methods.
Results: We replicated our previous lipids associations and reported novel associations between
lipids molecules and all phenotypes. A combination of 24 molecules classified AD patients with
.70% accuracy in a test and a validation data set, and we identified lipid signatures that predicted
disease progression (R2 5 0.10, test data set) and brain atrophy (R2 0.14, all test data sets except
left entorhinal cortex). We putatively identified a number of metabolic features including cholesteryl
esters/triglycerides and phosphatidylcholines.
Discussion: Blood lipids are promising AD biomarkers that may lead to new treatment strategies.
Date Issued
2016-09-28
Date Acceptance
2016-09-28
Citation
Alzheimers & Dementia, 2016, 13 (2), pp.140-151
ISSN
1552-5260
Publisher
Elsevier
Start Page
140
End Page
151
Journal / Book Title
Alzheimers & Dementia
Volume
13
Issue
2
Copyright Statement
2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. Thisis an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Subjects
Science & Technology
Life Sciences & Biomedicine
Clinical Neurology
Neurosciences & Neurology
Alzheimer's disease
Dementia
Brain atrophy
sMRI
Rate of cognitive decline
Lipidomics
Metabolomics
Biomarkers
Machine learning
Multivariate
Classification
Random forest
CEREBROSPINAL-FLUID
ER MEMBRANES
PLASMA
RISK
BIOMARKERS
DISCOVERY
IDENTIFICATION
DYSLIPIDEMIA
EPIDEMIOLOGY
TECHNOLOGY
Publication Status
Published